This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Phillips, N. C. Articles by Tsao, M. S. Search for Related Content PubMed PubMed Citation Articles by Phillips, N. C. Articles by Tsao, M. S.

Inhibition of Experimental Liver Tumor Growth in Mice by Liposomes Containing a Lipophilic Muramyl Dipeptide Derivative

Montreal General Hospital Research Institute, Montreal, Quebec H3G 1A4, Canada

The ability of liposomes containing a synthetic lipophilic muramyl dipeptide derivative, N-acetylmuramyl-L-alanyl-D-isoglutamyl-sn-glycerol dipalmitate (MDP-GDP), to inhibit the growth of experimental B16-F1 melanoma liver metastases in syngeneic C57BL/6 mice has been determined. Multiple i.v. injections of distearoylphosphatidylcholine:dimyristoylphosphatidylglycerol liposomes (1 µmol, 10:1 molar ratio) containing 0.1 to 1 µg of MDP-GDP given at 3- to 4-day intervals after seeding the livers with tumor cells resulted in a significant inhibition of the number of experimental B16 liver metastases. Control liposomes or free MDP (100 µg) failed to affect the number of experimental metastases. A single prophylactic injection of liposomes containing MDP-GDP was equally effective in eliciting a reduction in the number of experimental liver metastases. The ability of liposomal MDP-GDP to inhibit the growth of liver metastases correlated with its ability to induce Kupffer cell tumoricidal activity against the tumor cell targets; activation of C57BL/6 Kupffer cell activity in vitro was most effective with liposomal MDP-GDP, followed by liposomal MDP and free MDP. Only liposomal MDP-GDP and liposomal MDP were able to induce Kupffer cell tumoricidal activity in situ, free MDP being inactive. Liposomal muramyl dipeptide therapy using lipophilic derivatives would appear to be an effective treatment for hepatic metastases derived from primary tumors.

¹ To whom requests for reprints should be addressed, at the Montreal General Hospital Research Institute, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.

Received 3/24/88. Revised 11/ 4/88. Accepted 11/10/88.

This article has been cited by other articles:

				E. G. MacEwen, I. D. Kurzman, D. M. Vail, R. R. Dubielzig, K. Everlith, B. R. Madewell, C. O. Rodriguez Jr., B. Phillips, C. H. Zwahlen, J. Obradovich, et al. Adjuvant Therapy for Melanoma in Dogs: Results of Randomized Clinical Trials Using Surgery, Liposome-encapsulated Muramyl Tripeptide, and Granulocyte Macrophage Colony-stimulating Factor Clin. Cancer Res., December 1, 1999; 5(12): 4249 - 4258. [Abstract] [Full Text] [PDF]

				Y. Namba and N. Oku Liposomal Applications to Cancer Therapy Journal of Bioactive and Compatible Polymers, January 1, 1993; 8(2): 158 - 177. [PDF]